KEY POINTS
* Older adults who get the shingles vaccine have a nearly 50 percent reduced risk of acquiring the painful disease than unvaccinated older adults.* The shingles vaccine is more effective in adults in their 60s than 70s or older, due to a higher immune response.
Newswise — Older adults who get the shingles vaccine have a nearly 50 percent reduced risk of developing the often debilitating disease, finds a new evidence review from The Cochrane Library.
Shingles, which originates from the same virus as the childhood disease chickenpox, can severely impact quality of life for weeks or months.
Lead study author, Anna Gagliardi, Ph.D., professor of geriatrics and gerontology at Federal University in Sao Paulo, Brazil, explained, “The herpes zoster disease is an extremely painful condition that impacts the quality of patients’ lives. People over 60 are particularly susceptible to developing the disease, but fortunately nowadays we have a vaccine for it.”
The shingles virus remains dormant in the nervous system of anyone who had chickenpox. Later in life, when the immune system is more compromised, the virus may reappear in the form of shingles, a painful inflammation of sensory nerves.
The vaccine is more effective for those 60 to 69 years old compared with people 70 and older since younger adults typically have a stronger immune system. However, those in their 60s may experience more frequent side effects from the vaccine.
Gagilardi noted, “Adults over 70 have less immunity reaction from the vaccine, but the vaccine works. In general, the vaccine is well tolerated and it produces few systemic adverse reactions and only a mild or moderate adverse reaction at the site of the vaccination.”
Researchers analyzed the effectiveness of the zoster vaccine from eight randomized controlled trials that included 52,259 people in several European countries and the U.S. The principal study, the Shingles Prevention Study, followed 38,546 participants for at least 3 years and one month after being vaccinated.
Jonathan S. Anderson, M.D., internist with the Dean Health System in Madison, Wisconsin, said, “The meta-analysis confirms what we knew before and what we see in practice: that the zoster vaccine reduces the risk of developing shingles over subsequent years. Over the three years the study looked at the effects of the vaccine, the risk was cut in half. Fifty people would need to receive the vaccine for one person to benefit by not getting shingles. This is reasonable given that shingles is not only very painful, it can develop into a chronically painful condition which is often difficult to treat.”
Anderson added, “While the results of the study weren’t surprising it may provide some impetus to vaccinate people sooner when they are still in their 60s instead of waiting and continuing to discuss it with patients over time.”
TERMS OF USE: This story is protected by copyright. When reproducing any material, including interview excerpts, attribution to the Health Behavior News Service, and part of the Center for Advancing Health, is required. While the information provided in this news story is from the latest peer-reviewed research, it is not intended to provide medical advice or treatment recommendations. For medical questions or concerns, please consult a health care provider.
The Cochrane Library (http://www.thecochranelibrary.com) contains high quality health care information, including systematic reviews from The Cochrane Collaboration. These reviews bring together research on the effects of health care and are considered the gold standard for determining the relative effectiveness of different interventions.
Gagliardi AMZ, Gomes Silva BN, TorloniMR, Soares BGO. Vaccines for preventing herpes zoster in older adults. Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD008858. DOI: 10.1002/14651858.CD008858.pub2
RSS